<DOC>
	<DOCNO>NCT01191359</DOCNO>
	<brief_summary>Multicentre Phase II trial , compare two different administration route SLITonePLUS Birch regard pharmacodynamic efficacy tolerability .</brief_summary>
	<brief_title>Efficacy Tolerability Two Different Administration Routes With SLITonePLUS Birch</brief_title>
	<detailed_description />
	<criteria>A history Birch pollen allergy Positive skin prick test birch Positive specific IgE birch Exclusion criterion : Uncontrolled severe asthma ( FEV1 &lt; 70 % predict value spite adequate pharmacologic treatment ) Previous treatment immunotherapy birch crossreactingtree pollen allergen within previous 5 year Concomitant SLIT allergen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>